GSK evidence supports respiratory meds portfolio

GSK has broad respiratory meds portfolio.
GSK is to present evidence at ERS to support its growing respiratory medicines portfolio.

GlaxoSmithKline plc (GSK) is to profile the growing evidence base that supports its broad respiratory medicines portfolio at the European Respiratory Society (ERS) congress in Paris, France, 15-19 September 2018.

Data presented in 50 abstracts will underscore the therapeutic value of key medicines across a spectrum of patients with asthma and chronic obstructive pulmonary disease (COPD).

Data presented will include new analyses from clinical studies across the medicines portfolio. These data provide evidence of the role different treatments have in optimising the management of respiratory diseases by addressing the main areas of individual patient need. Findings include the effect on exacerbations, or worsening of the condition, that many COPD and asthma patients suffer, as well as on lung function, symptoms such as breathlessness and quality of life.

Data will also be presented assessing the benefit of treatments across disease severities and age groups.

New analyses of data from the landmark IMPACT study will help to clarify which patients can gain the greatest benefit from the different COPD combination treatment classes in the study, to provide further evidence on the right treatment for the right patient.